Company: BIAF
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001641172-25-025247
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-22
Form: DRS
Chunk 2
---
 the Common Stock Purchase Warrants,

Pre-Funded Warrants and Placement Agent Warrants</div>

We are offering up to [●] shares of our Common Stock, $0.007 par value per share (the “Common Stock”), together with common stock purchase warrants to purchase up to [●] shares of Common Stock (the “August 2025 Warrants”). Each share of our Common Stock, or a Pre-Funded Warrant in lieu thereof (as described below), is being sold together with one August 2025 Warrant to purchase one share of Common Stock. The shares of Common Stock and August 2025 Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The assumed public offering price for each share of Common Stock and accompanying August 2025 Warrant is $[●], which was the closing price of our Common Stock on The Nasdaq Capital Market (“Nasdaq”) on August [●], 2025. The August 2025 Warrants will have an exercise price per share of $[●], will be exercisable beginning on the effective date of shareholder approval of the issuance of the shares upon exercise of the August 2025 Warrants (“Warrant Shareholder Approval”), provided, however, if the Pricing Conditions (as defined below) are met, the warrants will be exercisable upon issuance (the “Initial Exercise Date”) and will expire on the five-year anniversary of the Initial Exercise Date. As used herein, “Pricing Conditions” means that the combined offering price per share and accompanying August 2025 Warrant is such that the Warrant Shareholder Approval is not required under the rules of the Nasdaq Stock Market LLC (“Nasdaq”) because either (i) the offering is an at-the-market offering under Nasdaq rules and such price equals or exceeds the sum of (a) the applicable “Minimum Price” per share under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of Common Stock underlying the August 2025 Warrants or (ii) the offering is a discounted offering where the pricing and discount (including attributing a value of $0.125 per whole share underlying the August 2025 Warrants) meet the pricing requirements under Nasdaq’s rules.

We are also offering to each purchaser whose purchase of shares of our Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4